Vyriad

Vyriad is a clinical-stage biotechnology company developing the next generation of targeted genetic therapies. Founded by scientists at Mayo Clinic, Vyriad has remained rooted in Rochester, Minnesota. Their team of over 90 scientists and supporting professionals bring their passion and diverse expertise from over 15 countries to Rochester, Minnesota. In collaboration with Regeneron, Mayo Clinic and other research and medical institutions, they have successfully developed oncolytic virotherapies derived from either vesicular stomatitis virus (VSV) or measles virus for the treatment of cancers. These therapies are now in ongoing Phase 1-2 clinical trials addressing multiple cancer types. Vyriad is building a state-of-the-art facility for manufacturing oncolytic virus anti-cancer vaccines in Rochester.